Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients-Reference-Cited by-同舟云学术

Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients

Published:2016-09-19 Issue:6 Volume:82 Page:1498-1508
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

von Richter Oliver¹,Massimini Giorgio²,Scheible Holger³,Udvaros Istvan⁴,Johne Andreas¹

Affiliation:

1. Merck KGaA; Clinical Pharmacology; 64293 Darmstadt Germany

2. Merck KGaA; Early Clinical Oncology; 64293 Darmstadt Germany

3. Merck KGaA; DMPK; 85567 Grafing Germany

4. PRA International; EDS Patient Pharmacology; 1076 Budapest Hungary

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.13078/fullpdf

Reference27 articles.

1. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands;Southan;Nucl Acids Res,2016

2. The Concise Guide to PHARMACOLOGY 2015/16: Enzymes;Alexander;Br J Pharmacol,2015

3. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo;Kim;Br J Haematol,2010

4. World Intellectual Property Organization WO2006045514. 3-arylamino pyridine derivatives 2006 https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2006045514&redirectedID=true

5. World Intellectual Property Organization WO2013178320. Solid state forms of n-((s)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide 2013 https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2013178320&redirectedID=true

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Study of the mass balance, biotransformation and safety of [14C]SHR8554, a novel μ-opioid receptor injection, in healthy Chinese subjects;Frontiers in Pharmacology;2023-09-14

2. Design, conduct, and interpretation of human mass balance studies and strategies for assessing metabolites-in-safety testing (MIST) in drug development;Overcoming Obstacles in Drug Discovery and Development;2023

3. CERN Large Hadron Collider (LHC) Radiation Source for Magnetic Resonance Biospectroscopy in Metabolic and Molecular Imaging and Diagnosis of Cancer;Journal of New Developments in Chemistry;2022-12-02

4. C20orf24 promotes colorectal cancer progression by recruiting Rin1 to activate Rab5‐mediated mitogen‑activated protein kinase/extracellular signal‐regulated kinase signalling;Clinical and Translational Medicine;2022-04

5. Retinal toxicities of systemic anticancer drugs;Survey of Ophthalmology;2022-01